Does tumor rupture during robot-assisted partial nephrectomy have an impact on mid-term oncologic outcome?

Abstract

Background. Intraoperative kidney tumor rupture (TR) can occur during robot-assisted partial nephrectomy (RAPN) in daily clinical practice, but there are no solid guidelines on the management and implications of it. The purpose of the study was to investigate the oncologic impact of TR, what a surgeon should do if this undesired event occurs, and how to avoid it.

Patients and methods. We retrospectively analyzed the first 100 patients who underwent RAPN at our center between 2018 and 2021. Patients were stratified into 2 groups (TR and no TR) and were compared according to patient, tumor, pathologic, perioperative and postoperative characteristics and oncologic outcome, using the Mann-Whitney U test and chi-squared test.

Results. Of the 100 patients, 14 had TR (14%); this occurred in tumors with higher RENAL nephrometry scores (P = 0.028) and mostly with papillary renal cell carcinomas (P = 0.043). Median warm ischemia time was longer for the TR group (22 vs 15 min, P = 0.026). In terms of oncologic outcomes, there were no cases of local or distant recurrence after a median observation time of 39 months (interquartile range, 31-47 months) in both groups. We observed positive surgical margins on the final oncologic report in one case in the no TR group.

Conclusions. Tumor rupture during RAPN is of no mid-term oncologic importance. We advise surgeons to proceed with tumor resection if this event occurs and abstain from conversion to radical nephrectomy or open partial nephrectomy.